

patients was found 505U/L. This was determined by ROC for diagnosis of PCOS was 621.54U/L with sensitivity was study was nearly consistent with this previous study; however prolidase level in PCOS compared to healthy individuals. Therefore, plasma prolidase exhibit a good diagnostic performance for the evaluation of PCOS.

Conclusion

ovary syndrome (PCOS) patients than healthy individuals. Area under curve (AUC) has showed very good discrimination important tool for the diagnosis of polycystic ovary syndrome.

Limitations

It was a single centre study with relatively small sample size. Moreover the sample was taken purposively; therefore

Recommendation

A multicenter prospective cohort study with large sample Follow up study is recommended for better evaluation of plasma prolidase with prognosis and outcome of polycystic ovary syndrome.

Acknowledgement

The authors greatly acknowledge Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh for their technical support.

References

publication.

References

1. Shermin S, Noor A, Jahan S. Polycystic ovary syndrome: a brief review with recent updates. Delta Medical College -RQDO
2. Bhatnager R, Nanda S, Dang AS. Plasma prolidase levels as a biomarker for polycystic ovary syndrome. Biomarkers LQHGLFLH

3. Kabel AM. Polycystic ovarian syndrome: insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treatment. Pharmaceutical Bioprocessing 4 (2016):7-12.

4. Bharathi RV, Swetha S, Neerajaa J, Madhavica JV, Janani DM, Rekha SN, Ramya S, Usha B. An epidemiological study in urban and rural population. Middle East Fertility Society Journal 22 (2017):313-6.

5. Duzdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction 31 (2016):2841-55.

6. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. Journal of pediatric and adolescent gynecology 24 (2011):223-7.

7. Ghosh S, Ghosh A. Assessment of risk factors for development of polycystic ovarian syndrome. diabetes1 (2017).

8. Fatema K, Das TR, Kazal RK, Mahamood S, Pervin HH, Noor F, et al. Prevalence and characteristics of polycystic ovarian syndrome in women attending in outpatient department of obstetrics and gynecology of Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. International Journal of Reproduction, Contraception, Obstetrics and Gynecology 10 (2021):830-6.

9. Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 102 (2017):604-12.

10. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients ZLWKSROFVWLFYDUVQURPHJHUWLWLDQVWHULOL (2003):1358-64.

11. Bhatnager R, Nanda S, Dang AS. Increased Prolidase /HYHODQWHUHGURPRQO3URQHLRPHZLWK3RO\ &VWLF2YDULDQURPHJURZWK

12. :RRGUX7. 6KHD /7KH UROH RI WKH H[WUDFHOOXDU matrix in ovarian follicle development. Reproductive sciences 14 (2007):6-10.

13. Tsuruda T, Costello-Boerrigter LC, Burnett JC. Matrix metalloproteinases: pathways of induction by bioactive PROHFQHVH DUWIDLOKHUHYLHZV

14. Hui KS, Lajtha A. Prolidase activity in brain: comparison with other organs. Journal of neurochemistry 30

15. Surazynski A, Milyk W, Palka J, Phang JM. Prolidase-dependent regulation of collagen biosynthesis. *Amino acids* 35 (2008):731-8.
16. Hilali N, Vural M, Camuzcuoglu H, Camuzcuoglu A, Aksoy N. Increased prolidase activity and oxidative stress in PCOS. *Clinical endocrinology* 79 (2013):105-10.
17. Sahmay S, Atakul N, Aydogan B, Aydın Y, Imamoglu M, Seyisoglu H. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. *ActaobstetriciaetgynecologicaScandinavica* 92 (2013):1369-74.
18. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Human reproduction* 33 (2018):1602-18.
19. Moini A, Eslami B. Familial associations between polycystic ovarian syndrome and common diseases. *Journal of assisted reproduction and genetics* 26 (2009):123-7.
20. Begum F. Clinical and hormonal profile of polycystic ovary syndrome. *Journal of SAFOG1* (2009):22-5.